Digital Health & Discovery Platform
@dhdp-ca.bsky.social did:plc:w6uj7tqg2364o3cs23opmtia
We combine Canadian expertise in artificial intelligence (AI) and precision medicine to improve healthcare for Canadians. www.dhdp.ca Led by the Terry Fox Research Institute @terryfoxresearch.bsky.social
En Bluesky desde el
- Seguidores
- 158
- Siguiendo
- 363
- Posts
- 411
- Días en rankings
- 0
Resumen
Digital Health & Discovery Platform (@dhdp-ca.bsky.social) es un usuario de Bluesky que se unió el 21 abril 2025. Tiene 158 seguidores, sigue a 363 cuentas y ha publicado 411 posts.
Apariciones en rankings
Los mejores días en que los posts de esta cuenta entraron en la lista diaria de Debya.
Esta cuenta aún no ha aparecido en un ranking diario.
Posts que le gustaron recientemente
Me gusta públicos de la red Bluesky.
HAPPENING NOW: Fueling Digital Health Innovation How can a $25M gift accelerate cancer research through AI, machine learning and big data? Charles Crosbie of the Terry Fox Research Institute explores how this investment can advance innovation across Canada’s public and private sectors. #PACT2026
Ver post🍁 Investing in future precision onocology leaders 🍁 MOHCCN is awarding $2.1 million to four outstanding early-career clinician-scientists through the 2026 Clinician-Scientist Awards. Read the full announcement: www.marathonofhopecancercentres.ca/impact/news-...
Ver postIs treatment working? Could it come back? For young people with Hodgkin lymphoma, uncertainty can be overwhelming. Dr. Tomohiro Aoki, a 2026 MOHCCN Clinician-Scientist Awardee, is developing a blood test to monitor treatment response and detect relapse earlier. Learn more: tinyurl.com/eskd7r68
Ver postThe immune system is designed to fight disease. So why can some brain tumours evade its attack? Dr. Charles Couturier, a neurosurgeon and researcher at McGill University, is working to find answers with support from a 2026 MOHCCN Clinician-Scientist Award. Learn more: tinyurl.com/5cvr3m5e
Ver postHow do we know when a more advanced treatment is the better choice? 2026 MOHCCN Clinician-Scientist Awardee, Dr. Rachel Glicksman will lead the ASPIRE clinical trial to assess whether adaptive SBRT improves patients’ quality of life and if it's cost-effective. Learn more: tinyurl.com/3zwarwen
Ver post
Cuentas que bloquea
En Bluesky los bloqueos son registros públicos.
Esta cuenta no bloquea a nadie.